Irvine, California-based Biosense Webster designed Optrell as a high-density diagnostic catheter powered by its Carto 3 system. It features small electrodes arranged in a fixed array formation. These provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases.
Optrell with TrueRef maps cases like persistent AFib, redo AFib ablation, atrial tachycardia and ventricular tachycardia.
Biosense Webster received FDA 510(k) clearance for Optrell with TrueRef in 2022. In addition to this U.S. launch, it plans to make the technology available in Japan later this year.
Get the full story at our sister site, Medical Tubing & Extrusion.